Cargando…
Clinical Outcome of Edoxaban vs. Vitamin K Antagonists in Patients with Atrial Fibrillation and Diabetes Mellitus: Results from a Multicenter, Propensity-Matched, Real-World Cohort Study
Diabetes mellitus (DM) is a chronic metabolic disease which is independently associated with unfavorable clinical outcomes in patients with atrial fibrillation (AF). Few real-world data are available about the clinical performance of non-vitamin K oral anticoagulants (NOACs) among patients with atri...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7356851/ https://www.ncbi.nlm.nih.gov/pubmed/32471222 http://dx.doi.org/10.3390/jcm9061621 |
_version_ | 1783558577023090688 |
---|---|
author | Russo, Vincenzo Attena, Emilio Rago, Anna Melillo, Enrico Di Micco, Pierpaolo Papa, Andrea Antonio Napolitano, Giovanni D’Onofrio, Antonio Golino, Paolo Nigro, Gerardo |
author_facet | Russo, Vincenzo Attena, Emilio Rago, Anna Melillo, Enrico Di Micco, Pierpaolo Papa, Andrea Antonio Napolitano, Giovanni D’Onofrio, Antonio Golino, Paolo Nigro, Gerardo |
author_sort | Russo, Vincenzo |
collection | PubMed |
description | Diabetes mellitus (DM) is a chronic metabolic disease which is independently associated with unfavorable clinical outcomes in patients with atrial fibrillation (AF). Few real-world data are available about the clinical performance of non-vitamin K oral anticoagulants (NOACs) among patients with atrial fibrillation and diabetes. The aim of our propensity score-matched cohort study was to compare the safety and effectiveness of Edoxaban versus well-controlled vitamin K antagonists (VKAs) therapy among this population. In this study, we considered patients with AF and diabetes on Edoxaban or VKAs therapy included in the multicenter Atrial Fibrillation Research Database (NCT03760874). The occurrence of major bleedings (MB) and thromboembolic events (a composite of ischemic stroke, transient ischemic attack, systemic embolism) was respectively considered primary safety and effectiveness outcome. We identified 557 AF patients with diabetes who received Edoxaban (n: 230) or VKAs (n: 327) treatment. After propensity score matching analysis, 135 Edoxaban and 135 VKA recipients with similar clinical characteristics were evaluated. The mean follow-up was 27 ± 3 months. The incidence rate of thromboembolic events (TE) was 3.0 per 100 person-years (1.11 in Edoxaban vs. 1.9 in the VKA group, hazard ratio (HR): 0.59; 95% confidence interval (CI), 0.14 to 2.52; p = 0.48). The incidence rate of major bleedings (MB) was 3.7 per 100 person-years (1.2 in Edoxaban vs. 2.7 in the VKA group, HR: 0.43; 95% CI: 0.10 to 1.40; p = 0.14). The incidence rate of intracranial hemorrhage was 0.35 per 100 person-years in Edoxaban vs. 0.74 in the VKA group (HR: 0.49; 95% CI: 0.05 to 5.54; p = 0.56). A positive net clinical benefit (NCB) of Edoxaban over VKAs was found (+1.39). Insulin therapy (HR: 1.76, p = 0.004) and glycated hemoglobin (HR: 1.17, p = 0.002) were found to be independent predictors of TE; moreover, the concomitant use of antiplatelet drugs (HR: 2.41, p = 0.001) was an independent predictor of MB. Conclusions: Our data support the hypothesis of the safety and efficacy of Edoxaban for use in patients with AF and diabetes, justified by a favorable NCB over VKAs. |
format | Online Article Text |
id | pubmed-7356851 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-73568512020-07-22 Clinical Outcome of Edoxaban vs. Vitamin K Antagonists in Patients with Atrial Fibrillation and Diabetes Mellitus: Results from a Multicenter, Propensity-Matched, Real-World Cohort Study Russo, Vincenzo Attena, Emilio Rago, Anna Melillo, Enrico Di Micco, Pierpaolo Papa, Andrea Antonio Napolitano, Giovanni D’Onofrio, Antonio Golino, Paolo Nigro, Gerardo J Clin Med Article Diabetes mellitus (DM) is a chronic metabolic disease which is independently associated with unfavorable clinical outcomes in patients with atrial fibrillation (AF). Few real-world data are available about the clinical performance of non-vitamin K oral anticoagulants (NOACs) among patients with atrial fibrillation and diabetes. The aim of our propensity score-matched cohort study was to compare the safety and effectiveness of Edoxaban versus well-controlled vitamin K antagonists (VKAs) therapy among this population. In this study, we considered patients with AF and diabetes on Edoxaban or VKAs therapy included in the multicenter Atrial Fibrillation Research Database (NCT03760874). The occurrence of major bleedings (MB) and thromboembolic events (a composite of ischemic stroke, transient ischemic attack, systemic embolism) was respectively considered primary safety and effectiveness outcome. We identified 557 AF patients with diabetes who received Edoxaban (n: 230) or VKAs (n: 327) treatment. After propensity score matching analysis, 135 Edoxaban and 135 VKA recipients with similar clinical characteristics were evaluated. The mean follow-up was 27 ± 3 months. The incidence rate of thromboembolic events (TE) was 3.0 per 100 person-years (1.11 in Edoxaban vs. 1.9 in the VKA group, hazard ratio (HR): 0.59; 95% confidence interval (CI), 0.14 to 2.52; p = 0.48). The incidence rate of major bleedings (MB) was 3.7 per 100 person-years (1.2 in Edoxaban vs. 2.7 in the VKA group, HR: 0.43; 95% CI: 0.10 to 1.40; p = 0.14). The incidence rate of intracranial hemorrhage was 0.35 per 100 person-years in Edoxaban vs. 0.74 in the VKA group (HR: 0.49; 95% CI: 0.05 to 5.54; p = 0.56). A positive net clinical benefit (NCB) of Edoxaban over VKAs was found (+1.39). Insulin therapy (HR: 1.76, p = 0.004) and glycated hemoglobin (HR: 1.17, p = 0.002) were found to be independent predictors of TE; moreover, the concomitant use of antiplatelet drugs (HR: 2.41, p = 0.001) was an independent predictor of MB. Conclusions: Our data support the hypothesis of the safety and efficacy of Edoxaban for use in patients with AF and diabetes, justified by a favorable NCB over VKAs. MDPI 2020-05-27 /pmc/articles/PMC7356851/ /pubmed/32471222 http://dx.doi.org/10.3390/jcm9061621 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Russo, Vincenzo Attena, Emilio Rago, Anna Melillo, Enrico Di Micco, Pierpaolo Papa, Andrea Antonio Napolitano, Giovanni D’Onofrio, Antonio Golino, Paolo Nigro, Gerardo Clinical Outcome of Edoxaban vs. Vitamin K Antagonists in Patients with Atrial Fibrillation and Diabetes Mellitus: Results from a Multicenter, Propensity-Matched, Real-World Cohort Study |
title | Clinical Outcome of Edoxaban vs. Vitamin K Antagonists in Patients with Atrial Fibrillation and Diabetes Mellitus: Results from a Multicenter, Propensity-Matched, Real-World Cohort Study |
title_full | Clinical Outcome of Edoxaban vs. Vitamin K Antagonists in Patients with Atrial Fibrillation and Diabetes Mellitus: Results from a Multicenter, Propensity-Matched, Real-World Cohort Study |
title_fullStr | Clinical Outcome of Edoxaban vs. Vitamin K Antagonists in Patients with Atrial Fibrillation and Diabetes Mellitus: Results from a Multicenter, Propensity-Matched, Real-World Cohort Study |
title_full_unstemmed | Clinical Outcome of Edoxaban vs. Vitamin K Antagonists in Patients with Atrial Fibrillation and Diabetes Mellitus: Results from a Multicenter, Propensity-Matched, Real-World Cohort Study |
title_short | Clinical Outcome of Edoxaban vs. Vitamin K Antagonists in Patients with Atrial Fibrillation and Diabetes Mellitus: Results from a Multicenter, Propensity-Matched, Real-World Cohort Study |
title_sort | clinical outcome of edoxaban vs. vitamin k antagonists in patients with atrial fibrillation and diabetes mellitus: results from a multicenter, propensity-matched, real-world cohort study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7356851/ https://www.ncbi.nlm.nih.gov/pubmed/32471222 http://dx.doi.org/10.3390/jcm9061621 |
work_keys_str_mv | AT russovincenzo clinicaloutcomeofedoxabanvsvitaminkantagonistsinpatientswithatrialfibrillationanddiabetesmellitusresultsfromamulticenterpropensitymatchedrealworldcohortstudy AT attenaemilio clinicaloutcomeofedoxabanvsvitaminkantagonistsinpatientswithatrialfibrillationanddiabetesmellitusresultsfromamulticenterpropensitymatchedrealworldcohortstudy AT ragoanna clinicaloutcomeofedoxabanvsvitaminkantagonistsinpatientswithatrialfibrillationanddiabetesmellitusresultsfromamulticenterpropensitymatchedrealworldcohortstudy AT melilloenrico clinicaloutcomeofedoxabanvsvitaminkantagonistsinpatientswithatrialfibrillationanddiabetesmellitusresultsfromamulticenterpropensitymatchedrealworldcohortstudy AT dimiccopierpaolo clinicaloutcomeofedoxabanvsvitaminkantagonistsinpatientswithatrialfibrillationanddiabetesmellitusresultsfromamulticenterpropensitymatchedrealworldcohortstudy AT papaandreaantonio clinicaloutcomeofedoxabanvsvitaminkantagonistsinpatientswithatrialfibrillationanddiabetesmellitusresultsfromamulticenterpropensitymatchedrealworldcohortstudy AT napolitanogiovanni clinicaloutcomeofedoxabanvsvitaminkantagonistsinpatientswithatrialfibrillationanddiabetesmellitusresultsfromamulticenterpropensitymatchedrealworldcohortstudy AT donofrioantonio clinicaloutcomeofedoxabanvsvitaminkantagonistsinpatientswithatrialfibrillationanddiabetesmellitusresultsfromamulticenterpropensitymatchedrealworldcohortstudy AT golinopaolo clinicaloutcomeofedoxabanvsvitaminkantagonistsinpatientswithatrialfibrillationanddiabetesmellitusresultsfromamulticenterpropensitymatchedrealworldcohortstudy AT nigrogerardo clinicaloutcomeofedoxabanvsvitaminkantagonistsinpatientswithatrialfibrillationanddiabetesmellitusresultsfromamulticenterpropensitymatchedrealworldcohortstudy |